The American Cancer Society estimates that more than 97,000 people in the United States will be diagnosed with colorectal cancer this year and will cause approximately 50,600 deaths. It is the third most common cancer in the United States and the second leading cause of cancer death.
Although colorectal cancer screening has been shown to be effective in reducing cancer deaths, researchers report that the number of screeners is too small. The current guidelines of the ACS recommend routine screening for general-risk groups 45 years of age and older, using high-sensitivity fecal examination or structural (visual) examination, and all positive results should be colonoscopy. Despite these recommendations, the study found significant differences in screening rates, including ethnicity, geographic area, and other socioeconomic factors.
tun maganin ciwon daji is a preventable disease, efforts are being made throughout the country to increase the screening rate of colorectal cancer, but the screening rate is only about 63%, while the screening rate of low-income and other vulnerable groups is often lower.
The latest research suggests that with stool immunochemical tests, or FIT kits, they can detect blood in stool and common symptoms of colon cancer. The patient can complete the test at home and return it to the provider for analysis. Patients with a positive result of the FIT kit test will be scheduled for colonoscopy.
A cikin binciken, kashi 21% na marasa lafiyar da suka karbi kayan aikin na FIT sun kammala gwajin, kuma mutane 18 da suka kammala gwajin na da sakamako mara kyau, kuma 15 daga cikin su na bukatar binciken kwakwaf. Daga cikin marasa lafiya 10 da suka kammala aikin binciken cikin gida, mara lafiya 1 yana da sakamako mara kyau.
Masu binciken suna shirin ci gaba da yin nazari ko za a iya aiwatar da wannan hanyar ganowa a kan sikeli mafi girma da ƙarin koyo game da fa'idar farashi da yadda za a ƙara yawan bincike kan ƙungiyoyi masu rauni.
